NCT07539610尚未招募1 期
Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors: A Prospective, Single-Arm Clinical Study
Institute of Hematology & Blood Diseases Hospital, China1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2026年4月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Safety evaluation of Sup19 CAR-T cell therapy in patients with hematologic malignancies who have failed prior CD19-targeted therapy or exhibit weak CD19 expression: dose-limiting toxicity (DLT) adverse events (with particular focus on CRS and ICANS)
研究概览
简要总结
Evaluation of Sup19 CAR-T cells in cases where previous CD19-targeted therapy has failed or where CD19 Evaluation of Safety and Efficacy in the Treatment of Low-Grade Hematological Malignancies: A Prospective, Single-Arm Clinical Study Research
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 69 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged ≥18 and <70 years, of any gender;
- •diagnosed with B-ALL/LBL according to the criteria of the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute Lymphoblastic Leukemia (2020.v1) and B-cell Lymphoma Clinical Practice Guidelines (2020.v1);
- •meeting either of the following two criteria: (1) Previous targeted CD19 therapy, including bispecific antibodies, ADC drugs, and CAR-T, with continued CD19 expression; (2) Patients with hematological malignancies who have not received CD19-targeted therapy in the past, with weakly positive CD19 expression;
- •At the time of screening, the number of blasts in the bone marrow is 25% (bone marrow morphology) and/or extramedullary lesions;
- •Meeting the diagnosis of relapsed/refractory B-ALL/LBL, including any of the following situations: a. Primary refractory patients who have not achieved complete remission after two cycles of standardized chemotherapy or patients who have not achieved complete remission after multiple salvage chemotherapy regimens; b. Patients who relapse within 12 months after achieving complete remission or relapse after 12 months of achieving complete remission and have not achieved complete remission after one or more courses of standard treatment induction; c. Patients who relapse after hematopoietic stem cell transplantation or after CAR-T therapy targeting the same target;
- •Other relapsed/refractory CD19 weakly expressing hematological malignancies;
- •Creatinine clearance rate > 60 ml/min (Cockcroft and Gault formula); for patients without liver involvement, total serum bilirubin < 3 times the upper limit of normal, and both serum ALT and AST < 5 times the upper limit of the normal range.
- •Echocardiography shows left ventricular ejection fraction (LVEF) of 250%;
- •Finger pulse oxygen saturation > 92%;--Estimated survival period of more than 3 months;
- •Estimated survival period of more than 3 months;
- •ECOG score of 0-2;
- •The subject or his/her legal guardian voluntarily participates in this trial and signs the informed consent form.
排除标准
- •Acute promyelocytic leukemia (APL);
- •presence of hereditary syndromes such as Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or any other known myelodysplastic syndrome;
- •uncontrolled active central nervous system leukemia (CNSL), i.e., cerebrospinal fluid (CSF) classification CNS 3;
- •prior administration of antineoplastic therapy before infusion; exclusion criteria include: a. Received systemic chemotherapy within 1 week (excluding pre-treatment); b. Those who have received monoclonal antibody treatment, with the time from the last monoclonal antibody infusion to the screening being less than 5 half-lives or 4 weeks (whichever is shorter); c. Received donor lymphocyte infusion (DLI) within 6 weeks;
- •Had uncontrolled severe active infection at screening;
- •Had a history of severe heart disease, including: severe heart dysfunction (according to the New York Heart Association (NYHA) cardiac function classification criteria, subjects with grade III or V cardiac dysfunction), myocardial infarction within 12 months or undergoing coronary angioplasty or stent placement, unstable angina pectoris, or electrocardiogram indicating a significantly prolonged QT interval (>480ms) or the investigator determined severe arrhythmia;
- •Had a history of head trauma, consciousness disorder, epilepsy, cerebrovascular ischemia, or cerebrovascular hemorrhagic disease, and required medication within the past 6 months;
- •Had hepatitis B surface antigen (HBsAg) greater than 10E6 IU/mL at screening; positive hepatitis C virus (HCV) antibody; positive human immunodeficiency virus (HIV) antibody; positive syphilis antibody; EBER positive or EBV copy number > upper limit of normal;
- •Those who require the use of steroid hormones during CAR-T infusion (except for those using inhaled steroid hormones locally); subjects who are receiving systemic steroid treatment before screening and whose study investigators determine that they need long-term systemic steroid treatment during the treatment period (excluding those using inhaled or local steroid hormones);
- •Subjects with treatable autoimmune diseases, immunodeficiency or those requiring immunosuppressive therapy;
- •Subjects who had acute graft-versus-host disease (GvHD) or moderate to severe chronic GvHD within 4 weeks before screening;
- •Subjects with a history of allergy to any component of the cell product;
- •Pregnant or lactating women, as well as male or female subjects who have reproductive capacity and cannot take effective contraceptive measures within 1 year after cell infusion (regardless of gender); male subjects who plan to conceive within 1 year after cell infusion; female subjects or their partners who plan to conceive within 1 year after cell infusion;
- •Any situation that the investigator considers may increase the risk for the subject or interfere with the test results.
研究组 & 干预措施
3 dose groups
Experimental
Using a dose escalation and rapid titration design, the CAR-T dose groups were (1) 0.5×10^6 CAR-T cells/kg; (2) 1×10^6 CAR-T cells/kg; (3) 3×10^6 CAR-T cells/kg.
干预措施: Sup19 CAR-T (Biological)
结局指标
主要结局
Safety evaluation of Sup19 CAR-T cell therapy in patients with hematologic malignancies who have failed prior CD19-targeted therapy or exhibit weak CD19 expression: dose-limiting toxicity (DLT) adverse events (with particular focus on CRS and ICANS)
时间窗: up to 28 after CAR-T cell infusion
次要结局
- Overall Survival,(OS）(The time from the first infusion of CAR-T cells to death due to any cause (Follow-up monitoring was conducted until 3 years after the infusion))
- Negative rate of Minimal Residual Disease（MRD）(28 days after the Sup19 CAR-T infusion)
- The proportion of patients who received hematopoietic stem cell transplantation under the alleviated condition(The proportion of subjects who achieved remission after infusion and who received HSCT. (Follow-up monitoring was conducted until 3 years after the infusion))
- The best response rate of Sup19 CAR-T cell therapy within 3 months(The proportion of patients achieving CR/CRi)(Sup19 CAR-T cell therapy within 3 months)
- Duration of response (DOR)(After the Sup19 CAR-T infusion, the time from the first achievement of CR/CRi + PR to disease recurrence or death due to leukemia (follow-up monitoring until 3 years after infusion).)
- Event-free Survival, (EFS）(The time from the administration of Sup19 CAR-T to the earliest occurrence of the event (follow-up monitoring until 3 years after infusion))
- Leukemia-free Survival, (LFS）(The time from the first occurrence of CR/CRi (ALL/LBL) to recurrence or death. (follow-up monitoring until 3 years after infusion))
研究者
研究点 (1)
Loading locations...
相似试验
暂停
1/2 期
Application of antiCD19 CAR T lymphocytes for the treatment of adult patients with B-cell acute lymphoblastic leukemia with resistance, relapse or detectable measurable residual disease. Phase I/II clinical trial (MERMAID1)2024-519808-27-00Medical University Of Warsaw20
尚未招募
1 期
CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant LymphomaAcute LeukemiaLymphomaNCT07383233Qi deng18
招募中
2 期
CARLA-M19 : “Prospective non-randomized phase I/II study investigating the safety of CD19 CAR-T cells in patients with refractory/relapsed AML (Acute Myeloïd Leukemia) expressing CD19.”2023-509212-29-01Centre Hospitalier Universitaire De Lille5
招募中
2 期
DK-CLIC-1901 CAR T-cells for treatment of patients with relapsed/refractory CD19 positive hematological malignancies (DAN-CART 1901)2024-515174-27-00Rigshospitalet20
Unknown
2 期
CAR-T 治疗 CD19+B 细胞恶性血液病的临床研究ChiCTR-OIC-16008291自筹